Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients
AUTOR(ES)
Pereira, Renata Freire Alves, Garcia, Rita de Cássia Nasser Cubel, Azevedo, Kátia Martins Lopes de, Setúbal, Sérgio, Siqueira, Marilda Agudo Mendonça Teixeira de, Oliveira, Solange Artimos de
FONTE
Mem. Inst. Oswaldo Cruz
DATA DE PUBLICAÇÃO
2014-04
RESUMO
Immunocompromised patients may develop severe chronic anaemia when infected by human parvovirus B19 (B19V). However, this is not the case in human immunodeficiency virus (HIV)-infected patients with good adherence to highly active antiretroviral treatment (HAART). In this study, we investigated the clinical evolution of five HIV-infected patients receiving HAART who had B19V infections confirmed by serum polymerase chain reaction. Four of the patients were infected with genotype 1a strains and the remaining patient was infected with a genotype 3b strain. Anaemia was detected in three of the patients, but all patients recovered without requiring immunoglobulin and/or blood transfusions. In all cases, the attending physicians did not suspect the B19V infections. There was no apparent relationship between the infecting genotype and the clinical course. In the HAART era, B19V infections in HIV-positive patients may be limited, subtle or unapparent.
Documentos Relacionados
- Parvovirus B19 seroconversion in a cohort of human immunodeficiency virus-infected patients
- Seroepidemiological study of human parvovirus B19 among human immunodeficiency virus-infected patients in a medium-sized city in Rio de Janeiro, Brazil
- Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
- Pharmacokinetics of Ritonavir and Delavirdine in Human Immunodeficiency Virus-Infected Patients
- Population Pharmacokinetics of Rifabutin in Human Immunodeficiency Virus-Infected Patients